MELBOURNE, Australia, Sept. 26, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and GenesisCare, the largest provider of integrated cancer care in Australia, today ...
Cancer screening reduced targeted cancer mortality without significantly increasing deaths from other causes. Meta-analysis of 17 studies found a 0.2% increase in off-target mortality rates in ...
Please provide your email address to receive an email when new articles are posted on . Rezpegaldesleukin is a first-in-class interleukin-2 receptor agonist that proliferates and activates regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results